Literature DB >> 18838599

Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used.

V Prakash, J S Lewis, J H Jorgensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18838599      PMCID： PMC2592869          DOI： 10.1128/AAC.00904-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  6 in total

1.  High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.

Authors:  Levita K Hidayat; Donald I Hsu; Ryan Quist; Kimberly A Shriner; Annie Wong-Beringer
Journal:  Arch Intern Med       Date:  2006-10-23

2.  Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.

Authors:  Darego O Maclayton; Katie J Suda; Krista A Coval; Cynthia B York; Kevin W Garey
Journal:  Clin Ther       Date:  2006-08       Impact factor: 3.393

3.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

4.  Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy.

Authors:  Pamela A Moise-Broder; George Sakoulas; George M Eliopoulos; Jerome J Schentag; Alan Forrest; Robert C Moellering
Journal:  Clin Infect Dis       Date:  2004-05-21       Impact factor: 9.079

5.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

6.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948
  6 in total
  39 in total

1.  Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods.

Authors:  Rodrigo M Paiva; Alice B Mombach Pinheiro Machado; Alexandre P Zavascki; Afonso L Barth
Journal:  J Clin Microbiol       Date:  2010-09-22       Impact factor: 5.948

Review 2.  Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections.

Authors:  Natasha E Holmes; Paul D R Johnson; Benjamin P Howden
Journal:  J Clin Microbiol       Date:  2012-05-16       Impact factor: 5.948

3.  Determination of vancomycin and daptomycin MICs by different testing methods for methicillin-resistant Staphylococcus aureus.

Authors:  Mark C Kruzel; Cole T Lewis; Kerry J Welsh; Evan M Lewis; Nicola E Dundas; John F Mohr; Lisa Y Armitige; Audrey Wanger
Journal:  J Clin Microbiol       Date:  2011-03-30       Impact factor: 5.948

4.  Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?

Authors:  J Kehrmann; M Kaase; F Szabados; S G Gatermann; J Buer; P-M Rath; J Steinmann
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-13       Impact factor: 3.267

5.  Correlation of methicillin-resistant Staphylococcus aureus vancomycin minimal inhibitory concentration results by Etest and broth microdilution methods with population analysis profile: lack of Etest overestimation of the MIC.

Authors:  R Khatib; K Riederer; S Shemes; A C Musta; S Szpunar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-10       Impact factor: 3.267

6.  Effects of storage on vancomycin and daptomycin MIC in susceptible blood isolates of methicillin-resistant Staphylococcus aureus.

Authors:  Franziska Ludwig; Becky Edwards; Timothy Lawes; Ian M Gould
Journal:  J Clin Microbiol       Date:  2012-08-01       Impact factor: 5.948

7.  International dissemination of Escherichia coli strains with discrepant behaviour in phenotypic antimicrobial susceptibility tests.

Authors:  D Creely; G Zambardi; A van Belkum; Wm M Dunne; M Peyret; J P Gayral; D Shortridge; C Shubert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-09       Impact factor: 3.267

8.  The Effect of Vancomycin on the Viability and Osteogenic Potential of Bone-Derived Mesenchymal Stem Cells.

Authors:  Elzaan Booysen; Hanél Sadie-Van Gijsen; Shelly M Deane; William Ferris; Leon M T Dicks
Journal:  Probiotics Antimicrob Proteins       Date:  2019-09       Impact factor: 4.609

Review 9.  Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections.

Authors:  Christopher Giuliano; Christopher Giulano; Krystal K Haase; Ronald Hall
Journal:  Expert Rev Anti Infect Ther       Date:  2010-01       Impact factor: 5.091

10.  Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method.

Authors:  Jiun-Ling Wang; Jann-Tay Wang; Wang-Huei Sheng; Yee-Chun Chen; Shan-Chwen Chang
Journal:  BMC Infect Dis       Date:  2010-06-07       Impact factor: 3.090
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.